The utility of targeting MCL-1 alone in solid tumours was recently demonstrated in lung adenocarcinoma where deletion of Mcl1 restricted tumour development and treatment with S63845 shown to delay tumour progression in vivo [43]. This evidence concerns the gene MCL1 and neoplasm.